drugset / Trial / NCT02947581
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
RandomizedParallel-groupDouble-blindTreatment
Summary
Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological disease in most of the world. When parasites locate in the cavities around the brain (subarachnoid NCC, SANCC), it becomes an aggressive, progressive and frequently lethal presentation. Current treatment regimens for SANCC have quite limited efficacy. The investigators propose to compare the current standard of care (a single antiparasitic drug, albendazole) with a combined regimen using two antiparasitic drugs simultaneously by adding praziquantel. The trial will enrol 164 patients in four centers, two in Peru, one in Ecuador, and one in Brasil.
Timeline
- Start
- 2016-11-14
- Primary completion
- 2020-08-21
- Completion
- 2021-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Praziquantel | Small molecule | 50 mg/kg | — |
| Comparator | Albendazole | Small molecule | 15 mg/kg | — |